Recursion Pharmaceuticals

RXRX on Nasdaq. Recursion uses artificial intelligence to discover medicines for patients. Market value $2.0bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to September 2026. Some use the latest annual report instead, as marked. Quality checks use five annual reports, the latest for the year to December 2025.

Capital spending looks too small to be complete, so we leave free cash flow out.

Should I look at this?

Look carefully before going further

Read the warning sign in its own filings

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
annual report to December 2025
n/a

We could not compute this from the filings.

Price to profit
past 12 months to September 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
-103.5%five-year median

Each dollar kept in the business earns -103 cents a year. Above 10 is good.

Quality score: 40 of 100. Price score: 16 of 100. Our list needs 70 on quality and 60 on price.

$2.45 a share, at its 1-year low

Over the past year the price has ranged from $2.44 to $5.24.

Pays no dividend

Prices from Friday’s close (20 November).

Five years of cash, in billions

-0.2
-0.1
-0.3
-0.4
n/a
20212022202320242025
Revenue
$10m$40m$45m$59m$75m
Operating margin
-1795.8%-616.7%-785.3%-814.1%-867.9%
Debt to equity
0.00n/a0.000.030.02
Shares outstanding
0.17bn0.19bn0.23bn0.40bn0.62bn

Health checks

  • Free cash flow positive0 of 4 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)4 of 9
  • Profit backed by cash (accruals)No
  • Debt0.02× equity
  • Revenue growth, five yearsStrong, 64.6% a year
  • Buying back its own sharesNo, 266% more shares since 2021

The quarter to September 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $19 million last quarter, up 258% on a year ago.
  • A loss of $119 million, compared with a loss of $162 million a year ago.
  • It loses 725 cents on each $1 of sales, compared with 1656 cents a year earlier.
  • 21% more shares than a year ago. Each share owns a bit less of the company.
  • It has $538 million more cash than debt, down from $639 million a year ago.
  • Sales grew on a year ago in 2 of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
December 2024$5m
March 2025$15m
June 2025$19m
September 2025$5m
December 2025$36m
March 2026$6m
June 2026$8m
September 2026$19m
Profit by quarter
Profit by quarter
Quarter toAmount
December 2024-$179m
March 2025-$202m
June 2025-$172m
September 2025-$162m
December 2025-$108m
March 2026-$118m
June 2026-$131m
September 2026-$119m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
25 February 2026
Next quarterly (estimated, 10-Q)
1 February 2027

Who owns it

None of the long-term investors we follow own it. 343 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

6 investors own more than 5%.

  • BlackRock, Inc.
    Passive investor
    8.5%+1.3 pts
    Since 30 June 2026
  • at least 8.4%+1.1 pts
    (filed with 1 related holder)
    Since 30 September 2026
  • 6.0%
    Since 30 June 2026
  • STATE STREET CORPORATION
    Passive investor
    5.6%−1.0 pts
    Since 30 September 2026
  • 5.1%
    Since 30 June 2026
  • at least 2.0%
    (filed with 3 related holders)
    Since 31 December 2024
  • BAILLIE GIFFORD & CO
    Passive investor
    Sold down below 5%
    Since 31 December 2025
  • MDC Capital Partners (Ventures) GP, LP
    Sold down below 5%
    Since 20 November 2024
    What they said

    On March 31, 2023, MIC LP transferred the 1,388,889 Common Shares that it then held to MCAS. As a result, as of such time, MCAS directly held 1,388,889 Common Shares and MIC LP ceased to beneficially own any Common Shares. In addition, the Issuer and Exscientia plc, a public…

    Read the filing
  • The Vanguard Group
    Passive investor
    Sold down below 5%
    Since 13 March 2026

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 6 sold $7m, $7m of it under preset trading plans.

  • Borgeson Blake
    Director
    Sold
    under a preset trading plan
    Date
    3 November 2026
    Shares
    40,000
    Price
    $3.88
    Value
    $155,200
  • Borgeson Blake
    Director
    Sold
    under a preset trading plan
    Date
    6 October 2026
    Shares
    50,000
    Price
    $4.84
    Value
    $242,000
  • HERSHBERG ROBERT
    Director
    Sold
    under a preset trading plan
    Date
    6 October 2026
    Shares
    25,000
    Price
    $5.00
    Value
    $125,000
  • Khan Najat
    CEO and President, Director
    Sold
    under a preset trading plan
    Date
    8 September 2026
    Shares
    22,408
    Price
    $3.52
    Value
    $78,822
  • Borgeson Blake
    Director
    Sold
    under a preset trading plan
    Date
    1 September 2026
    Shares
    30,000
    Price
    $3.34
    Value
    $100,200
  • Borgeson Blake
    Director
    Sold
    under a preset trading plan
    Date
    4 August 2026
    Shares
    30,000
    Price
    $3.25
    Value
    $97,500
  • Borgeson Blake
    Director
    Sold
    under a preset trading plan
    Date
    7 July 2026
    Shares
    40,000
    Price
    $3.96
    Value
    $158,500
  • Bumpus Namandje
    Director
    Sold
    under a preset trading plan
    Date
    18 June 2026
    Shares
    3,963
    Price
    $3.18
    Value
    $12,602
  • Khan Najat
    CEO and President, Director
    Sold
    under a preset trading plan
    Date
    5 June 2026
    Shares
    23,588
    Price
    $3.58
    Value
    $84,445
  • Gibson Christopher
    Director
    Sold
    under a preset trading plan
    Date
    5 June 2026
    Shares
    40,000
    Price
    $3.62
    Value
    $144,800

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

1 serious warning sign in Recursion Pharmaceuticals’ filings.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 25 Feb 2026, plus the 10-Q filed 2 Nov 2026 and 8 later 8-Ks.

  • Weak checks on its own accounts

    Serious

    The company said its checks on its own accounts did not work at the end of its latest quarter. Mistakes could slip into the numbers.

    “Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2026, our disclosure controls and procedures were ineffective due to the material weaknesses in internal control over financial reporting disclosed in Part II, Item 9A of our Annual Report on Form 10-K for the year ended December 31, 2025.”
    Show the full paragraph
    Our management has evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives as management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2026, our disclosure controls and procedures were ineffective due to the material weaknesses in internal control over financial reporting disclosed in Part II, Item 9A of our Annual Report on Form 10-K for the year ended December 31, 2025.

    From the 10-Q filed 2 November 2026, Part I, Item 4. Controls and Procedures. Read it in the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.